VEEV

301.55

-1.25%↓

A

142.21

+2.38%↑

HQY

91.49

+4.05%↑

PHR.US

23.46

-0.34%↓

KALV

11.39

+4.3%↑

VEEV

301.55

-1.25%↓

A

142.21

+2.38%↑

HQY

91.49

+4.05%↑

PHR.US

23.46

-0.34%↓

KALV

11.39

+4.3%↑

VEEV

301.55

-1.25%↓

A

142.21

+2.38%↑

HQY

91.49

+4.05%↑

PHR.US

23.46

-0.34%↓

KALV

11.39

+4.3%↑

VEEV

301.55

-1.25%↓

A

142.21

+2.38%↑

HQY

91.49

+4.05%↑

PHR.US

23.46

-0.34%↓

KALV

11.39

+4.3%↑

VEEV

301.55

-1.25%↓

A

142.21

+2.38%↑

HQY

91.49

+4.05%↑

PHR.US

23.46

-0.34%↓

KALV

11.39

+4.3%↑

Search

Medtronic PLC

Atidarymo kaina

SektoriusSveikatos priežiūra

97.82 -0.48

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

96.74

Max

98.48

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-17M

1B

Pardavimai

-349M

8.6B

P/E

Sektoriaus vid.

26.031

35.739

Pelnas, tenkantis vienai akcijai

1.26

Dividendų pajamingumas

2.98

Pelno marža

12.124

Darbuotojai

95,000

EBITDA

-50M

2.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+1.86% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.98%

3.08%

Kitas uždarbis

2025-11-18

Kitas dividendų mokėjimo data

2025-10-17

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.9B

121B

Ankstesnė atidarymo kaina

98.3

Ankstesnė uždarymo kaina

97.82

Naujienos nuotaikos

By Acuity

35%

65%

140 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Medtronic PLC Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-19 11:39; UTC

Uždarbis

Medtronic Posts Higher 1Q Revenue, Boosts Outlook as Tariffs Ease

2025-05-21 11:38; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

2025-08-19 20:33; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

These Stocks Moved the Most Today: Intel, Home Depot, Palo Alto, Viking Therapeutics, Palantir, Medtronic, and More -- Barrons.com

2025-08-19 17:41; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

2025-08-19 13:35; UTC

Karštos akcijos

Stocks to Watch Tuesday: Intel, Medtronic, Home Depot -- WSJ

2025-08-19 12:48; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

2025-08-19 11:27; UTC

Uždarbis

Medtronic Posts Earnings Beat and Elliott Buys Stake. The Stock Falls Anyway. -- Barrons.com

2025-08-19 10:51; UTC

Uždarbis

Medtronic Sees FY26 Reported Revenue Growth 6.5%-6.8% >MDT

2025-08-19 10:50; UTC

Uždarbis

Medtronic Had Seen FY26 Adjusted EPS $5.50-$5.60 >MDT

2025-08-19 10:50; UTC

Uždarbis

Medtronic Raises FY26 View To Adj EPS $5.60-Adj EPS $5.66 >MDT

2025-08-19 10:50; UTC

Uždarbis

Medtronic Cuts FY26 Potential Tariff Impact View to About $185M From $200M-$350M >MDT

2025-08-19 10:49; UTC

Uždarbis

Medtronic Raises FY26 Adjusted EPS Growth View to About 4.5% From About 4%, Excluding Potential Tariff Impact >MDT

2025-08-19 10:48; UTC

Uždarbis

Medtronic Still Sees FY26 Organic Revenue Up About 5% >MDT

2025-08-19 10:45; UTC

Uždarbis

Medtronic 1Q Medical Surgical Portfolio Rev $2.08B >MDT

2025-08-19 10:45; UTC

Uždarbis

Medtronic 1Q Cardiovascular Portfolio Rev $3.29B >MDT

2025-08-19 10:45; UTC

Uždarbis

Medtronic 1Q Neuroscience Portfolio Rev $2.42B >MDT

2025-08-19 10:45; UTC

Uždarbis

Medtronic 1Q Organic Revenue Up 4.8% >MDT

2025-08-19 10:45; UTC

Uždarbis

Medtronic 1Q EPS 81c >MDT

2025-08-19 10:45; UTC

Uždarbis

Medtronic 1Q Net $1.04B >MDT

2025-08-19 10:45; UTC

Uždarbis

Medtronic 1Q Diabetes Rev $721M >MDT

2025-08-19 10:45; UTC

Uždarbis

Medtronic 1Q Sales $8.58B >MDT

2025-08-19 10:45; UTC

Uždarbis

Medtronic 1Q Adj EPS $1.26 >MDT

2025-08-19 09:12; UTC

Karštos akcijos

Stocks to Watch Tuesday: Intel, Palo Alto, Tegna, Home Depot -- WSJ

2025-06-12 13:01; UTC

Įsigijimai, susijungimai, perėmimai

Medtronic Targeting Completion of Planned Separation Within 18 Mos of Initial Announcement >MDT

2025-05-21 17:23; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

2025-05-21 11:39; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

2025-05-21 10:52; UTC

Uždarbis

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

2025-05-21 10:51; UTC

Uždarbis

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

2025-05-21 10:50; UTC

Uždarbis

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

2025-05-21 10:49; UTC

Uždarbis

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

Akcijų palyginimas

Kainos pokytis

Medtronic PLC Prognozė

Kainos tikslas

By TipRanks

1.86% į viršų

12 mėnesių prognozė

Vidutinis 100.16 USD  1.86%

Aukščiausias 115 USD

Žemiausias 78 USD

Remiantis 25 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Medtronic PLC kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

25 ratings

12

Pirkti

12

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

83.26 / 84.875Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

140 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
help-icon Live chat